Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E |
| Therapy | Capecitabine + Cetuximab + Encorafenib + Oxaliplatin |
| Indication/Tumor Type | colon cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E | colon cancer | sensitive | Capecitabine + Cetuximab + Encorafenib + Oxaliplatin | Guideline | Actionable | Braftovi (encorafenib) in combination with Erbitux (cetuximab) and CAPEOX is included in guidelines as an initial therapy (category 2A) for patients with advanced or metastatic colon cancer harboring BRAF V600E (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |